“New NLRP3 Inflammasome Inhibitor Discovered by Japan Tobacco Inc. Shows Potential as Therapeutic Agent for Glomerulonephritis”

https://pubmed.ncbi.nlm.nih.gov/38116417

Researchers from Japan Tobacco Inc. have discovered a new class of NLRP3 inflammasome inhibitors, compound 32, which shows potential as a therapeutic agent for glomerulonephritis.